Showing 1,181 - 1,200 results of 27,650 for search '(( 50 ((mean decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (we decrease)) ))', query time: 1.14s Refine Results
  1. 1181

    Molecular Mimics of Classic P-Glycoprotein Inhibitors as Multidrug Resistance Suppressors and Their Synergistic Effect on Paclitaxel by Moustafa E. El-Araby (3626396)

    Published 2017
    “…On the other hand, combination of PTX and the non-cytotoxic Cur1-12V (10 μM) significantly decreased the IC<sub>50</sub> of PTX to 3.8 nM as well as the resistant fraction to 16.2%. …”
  2. 1182
  3. 1183
  4. 1184
  5. 1185
  6. 1186
  7. 1187
  8. 1188
  9. 1189
  10. 1190
  11. 1191
  12. 1192
  13. 1193
  14. 1194
  15. 1195
  16. 1196

    Evaluation of ethanol extract of Punica granatum (Pomegranate) peel decrease in viral replication of BoHV-1 in Colorado murine embryos experimentally infected by Eduardo Gimenes Palazzi (5671100)

    Published 2018
    “…The murine embryos treated with PgEE showed satisfactory results: no morphological changes, cleavage rate similar to controls, despite the detection of the presence of virus by nested PCR and TEM, there was a decrease of the viral titer after the treatment with this extract, which suggests interference of this treatment in the viral cycle BoHV-1 Colorado without altering the embryo development.…”
  17. 1197

    Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  18. 1198

    Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  19. 1199

    Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  20. 1200